Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. During digestion, food moves through the stomach and small intestine into the colon. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Some of the commonly seen symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel movements. Colorectal cancer is a result of uncontrolled cell growth that occurs in the appendix, colon, and the rectum region.

1. Colorectal Cancer Treatment Market Research Report by Geographical Analysis
and Forecast to 2024
Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of
the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water
and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the
rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which
may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding
and removing polyps can prevent colorectal cancer. During digestion, food moves through the
stomach and small intestine into the colon. Most colorectal cancers are adenocarcinomas (cancers
that begin in cells that make and release mucus and other fluids). Some of the commonly seen
symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel
movements. Colorectal cancer is a result of uncontrolled cell growth that occurs in the appendix,
colon, and the rectum region.
According to American Cancer Society, in United States when men and women are considered
individually colorectal cancer is the third prominent cause of cancer-related mortality, and the
second prominent cause when both sexes are combined. With the use of fecal occult blood tests and
colonoscopies, which check for blood in the stool the deaths from colorectal cancer have decreased.
Ageing, fatty diet, excessive consumption of red meat or alcohol, male gender, obesity, smoking are
the most commonly observed causes for colorectal cancer. Most colorectal cancers originate as a
polyp, a growth in the tissue that lines the internal surface of the rectum or colon and it is common
in people older than 50 years of age, and most are not cancer.
Browse full report on Colorectal Cancer Treatment Market -
http://www.transparencymarketresearch.com/colorectal-cancer-treatment-market.html
The global market for colorectal cancer market is segmented on basis of treatment options,
Colorectal Cancer Stage, end user and geography:
Segmentation by Diagnosis
Fecal Occult Blood Tests
Stool DNA test
Sigmoidoscopy
Colonoscopy
Virtual Colonoscopy
Double-contrast Barium Enema
Others
Segmentation by Treatment Options
Surgery

2. Radiation therapy
Chemotherapy
Targeted therapy
Others
Segmentation by Colorectal Cancer Stage
Stage 0
Stage I
Stage II
Stage III
Stage IV (Metastatic)
Increasing adoption of western diet which are high in fat and low in fiber is expected to boost the
growth of colorectal cancer market over the forecast period. Based on diagnosis, colorectal cancer
are classified as fecal occult blood tests, stool DNA test, sigmoidoscopy, colonoscopy, virtual
colonoscopy, double-contrast barium enema, others.
Based on treatment option, colorectal cancer are classified as surgery, radiation therapy,
chemotherapy and targeted therapy. Surgery remains the most effective treatment for colorectal
cancer. Radiation therapy reduces the chance of cancer spread or recurrence and is effective as
additional or adjuvant therapy either before or after surgery. The segment is expected to grow
rapidly over the forecast period due to increasing technological advancement and increasing
awareness.
Based on colorectal cancer stage, colorectal cancer has been segmented into stage 0, stage I, stage
II, stage III, and stage IV (metastatic). According to National Cancer Institute, in 2016, an estimated
134,490 people in the United States will be diagnosed with colorectal cancer and 49,190 people will
die from it. In general, stages 0, I, II, and III are often curable with surgery. Patients with stage II
and III rectal cancer receives radiation therapy with chemotherapy either before or after surgery.
Patients with stage III colorectal cancer, and some with stage II, receive chemotherapy after surgery
to increase the chance of eliminating the disease. Stage IV is not often curable, but it effects can be
reduced, and the growth of the cancer and the symptoms of the disease can be managed.
On the basis of regional presence, global colorectal cancer market is segmented into five key
regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North
America is expected to lead the global colorectal cancer market for due to aging population. Due to
increase in screening of colorectal cancer and changes in some risk factors such as a decline in
smoking and consumption of alcohol is decreasing the rate of new colorectal cancer cases and
deaths among adults aged 50 years and above.
Some of the major players in global colorectal cancer market are Hoffmann La Roche, Debiopharm
Group, Merck KGaA, Vaccinogen BD, AEterna Zentaris, and Keryx Biopharmaceuticals, Inc., etc.
Request for brochure of this report -
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15344
About Us
Transparency Market Research (TMR) is a market intelligence company, providing global
business information reports and services. Our exclusive blend of quantitative forecasting and
trends analysis provides forward-looking insight for thousands of decision makers. TMR’s

3. experienced team of analysts, researchers, and consultants, use proprietary data sources and various
tools and techniques to gather, and analyze information. Our business offerings represent the latest
and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals,
chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and
technology. These reports provide in-depth analysis and deep segmentation to possible micro levels.
With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide
clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com